博邁科(603727.SH):子公司簽訂1.4億美元重大合同
格隆匯10月10日丨博邁科(603727.SH)公佈,全資子公司天津博邁科海洋工程有限公司與MODEC子公司OFS、ABB簽署了BM-C-33FPSO項目合同,合同金額合計約為1.4億美元,由固定價格部分加當前預估的可變工作量核算金額部分組成,此工作包分成了化學撬合同、電氣間合同、詳細設計合同、上部模塊合同四部分分別與天津博邁科進行了簽署。
此工作包主要分成化學撬合同、電氣間合同、詳細設計合同、上部模塊合同四部分分別與天津博邁科進行了簽署。主要工作範圍涵蓋FPSO化學撬、電氣間及上部模塊的詳細設計、加工設計、材料採購、建造等工作。此艘FPSO建造完成後將部署在巴西近海坎波斯盆地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.